Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded up 23.6% during trading on Friday . The company traded as high as GBX 4.70 ($0.06) and last traded at GBX 4.33 ($0.05). 77,650,875 shares were traded during mid-day trading, an increase of 186% from the average session volume of 27,131,590 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Price Performance
The company has a fifty day moving average price of GBX 1.40 and a 200 day moving average price of GBX 1.65. The company has a market capitalization of £18.70 million, a P/E ratio of -449.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Articles
- Five stocks we like better than ImmuPharma
- Buy P&G Now, Before It Sets A New All-Time High
- Walgreens Stock Poised for a Rebound: Why Analysts Are Bullish
- Why Are Stock Sectors Important to Successful Investing?
- Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns
- 3 Small Caps With Big Return Potential
- Is Domino’s Recent Dip a Recipe for Long-Term Gains?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.